GALT - Galectin Therapeutics GAAP EPS of -$0.65 in-line
2023-03-30 08:20:04 ET
- Galectin Therapeutics press release ( NASDAQ: GALT ): FY GAAP EPS of -$0.65 in-line.
- As of December 31, 2022, the Company had $18.6 million of cash and cash equivalents. Additionally, the Company has $50 million remaining available under a $60 million line of credit provided by its chairman to fund operations. The Company believes it has sufficient cash to fund currently planned operations and research and development activities through at least December 31, 2024.
- The Company expects that it will require more cash to fund operations after December 31, 2024 and believes it will be able to obtain additional financing as needed.
- Shares -1.46% PM.
For further details see:
Galectin Therapeutics GAAP EPS of -$0.65 in-line